Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144674 | 1.00 | NTRK1 (1.00) | NTRK1IGF1R | |
| SCHEMBL4144068 | 1.00 | NTRK1 (1.00) | NTRK1IGF1R | |
| SCHEMBL4891282 | 0.94 | NTRK1 (0.88) | NTRK1IGF1R | |
| SCHEMBL4068914 | 0.93 | NTRK1 (0.87) | NTRK1IGF1R | |
| SCHEMBL23216996 | 0.91 | NTRK1 (0.83) | NTRK1IGF1R | |
| SCHEMBL3342109 | 0.91 | NTRK1 (0.83) | NTRK1IGF1R | |
| SCHEMBL4155699 | 0.91 | NTRK1 (0.83) | NTRK1IGF1R | |
| SCHEMBL4151532 | 0.91 | NTRK1 (0.83) | NTRK1IGF1R | |
| SCHEMBL4160280 | 0.89 | NTRK1 (0.83) | NTRK1IGF1R | |
| SCHEMBL4834967 | 0.89 | NTRK1 (0.80) | NTRK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | claimed |
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| EP-1877057-A1 | USE OF PYRAZOLYL-PYRIMIDINE DERIVATIVES IN THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006115452-A1 | USE OF PYRAZOLYL-PYRIMIDINE DERIVATIVES IN THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | P2RX3, DPYD, TYMP | NTRK1 3656/4885IGF1R 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.